ID   KCC4_HUMAN              Reviewed;         473 AA.
AC   Q16566; D3DSZ7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Calcium/calmodulin-dependent protein kinase type IV;
DE            Short=CaMK IV;
DE            EC=2.7.11.17;
DE   AltName: Full=CaM kinase-GR;
GN   Name=CAMK4; Synonyms=CAMK, CAMK-GR, CAMKIV;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8089075; DOI=10.1093/oxfordjournals.jbchem.a124387;
RA   Kitani T., Okuno S., Fujisawa H.;
RT   "cDNA cloning and expression of human calmodulin-dependent protein
RT   kinase IV.";
RL   J. Biochem. 115:637-640(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cerebellum, and Thymus;
RX   PubMed=8194751; DOI=10.1016/0378-1119(94)90260-7;
RA   Bland M.M., Monroe R.S., Ohmstede C.A.;
RT   "The cDNA sequence and characterization of the Ca2+/calmodulin-
RT   dependent protein kinase-Gr from human brain and thymus.";
RL   Gene 142:191-197(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=8107230;
RA   Mosialos G., Hanissian S.H., Jawahar S., Vara L., Kieff E.,
RA   Chatila T.A.;
RT   "A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed
RT   after transformation of primary human B lymphocytes by Epstein-Barr
RT   virus (EBV) is induced by the EBV oncogene LMP1.";
RL   J. Virol. 68:1697-1705(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=8397199;
RA   Hanissian S.H., Frangakis M., Bland M.M., Jawahar S., Chatila T.A.;
RT   "Expression of a Ca2+/calmodulin-dependent protein kinase, CaM kinase-
RT   Gr, in human T lymphocytes. Regulation of kinase activity by T cell
RT   receptor signaling.";
RL   J. Biol. Chem. 268:20055-20063(1993).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, DOMAIN AUTOINHIBITORY, AND MUTAGENESIS
RP   OF 309-HIS--THR-312 AND 320-PHE-ASN-321.
RX   PubMed=7961813;
RA   Tokumitsu H., Brickey D.A., Glod J., Hidaka H., Sikela J.,
RA   Soderling T.R.;
RT   "Activation mechanisms for Ca2+/calmodulin-dependent protein kinase
RT   IV. Identification of a brain CaM-kinase IV kinase.";
RL   J. Biol. Chem. 269:28640-28647(1994).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF CREB1, AND SUBCELLULAR LOCATION.
RX   PubMed=8065343; DOI=10.1128/MCB.14.9.6107;
RA   Matthews R.P., Guthrie C.R., Wailes L.M., Zhao X., Means A.R.,
RA   McKnight G.S.;
RT   "Calcium/calmodulin-dependent protein kinase types II and IV
RT   differentially regulate CREB-dependent gene expression.";
RL   Mol. Cell. Biol. 14:6107-6116(1994).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8980227; DOI=10.1016/S0092-8674(00)81816-4;
RA   Bito H., Deisseroth K., Tsien R.W.;
RT   "CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus
RT   duration-dependent switch for hippocampal gene expression.";
RL   Cell 87:1203-1214(1996).
RN   [10]
RP   ENZYME REGULATION, PHOSPHORYLATION AT SER-12; SER-13 AND THR-200, AND
RP   MUTAGENESIS OF SER-12 AND SER-13.
RX   PubMed=8702940; DOI=10.1074/jbc.271.35.21542;
RA   Chatila T., Anderson K.A., Ho N., Means A.R.;
RT   "A unique phosphorylation-dependent mechanism for the activation of
RT   Ca2+/calmodulin-dependent protein kinase type IV/GR.";
RL   J. Biol. Chem. 271:21542-21548(1996).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF ELK1; JUN AND ATF2, AND MUTAGENESIS OF
RP   THR-200.
RX   PubMed=8855261; DOI=10.1073/pnas.93.20.10803;
RA   Enslen H., Tokumitsu H., Stork P.J., Davis R.J., Soderling T.R.;
RT   "Regulation of mitogen-activated protein kinases by a
RT   calcium/calmodulin-dependent protein kinase cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:10803-10808(1996).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF STMN1.
RX   PubMed=9154845; DOI=10.1128/MCB.17.6.3459;
RA   Melander Gradin H., Marklund U., Larsson N., Chatila T.A.,
RA   Gullberg M.;
RT   "Regulation of microtubule dynamics by Ca2+/calmodulin-dependent
RT   kinase IV/Gr-dependent phosphorylation of oncoprotein 18.";
RL   Mol. Cell. Biol. 17:3459-3467(1997).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF MEF2D, AND MUTAGENESIS OF LYS-75.
RX   PubMed=10617605; DOI=10.1074/jbc.275.1.197;
RA   Blaeser F., Ho N., Prywes R., Chatila T.A.;
RT   "Ca(2+)-dependent gene expression mediated by MEF2 transcription
RT   factors.";
RL   J. Biol. Chem. 275:197-209(2000).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=12065094; DOI=10.1016/S0304-3835(02)00107-6;
RA   Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawa I.;
RT   "Ca(2+)/calmodulin-dependent protein kinase IV expression in
RT   epithelial ovarian cancer.";
RL   Cancer Lett. 183:185-193(2002).
RN   [15]
RP   ENZYME REGULATION, INTERACTION WITH PROTEIN PHOSPHATASE 2A,
RP   PHOSPHORYLATION AT THR-200, AND MUTAGENESIS OF 320-PHE-ASN-321.
RX   PubMed=15143065; DOI=10.1074/jbc.M404523200;
RA   Anderson K.A., Noeldner P.K., Reece K., Wadzinski B.E., Means A.R.;
RT   "Regulation and function of the calcium/calmodulin-dependent protein
RT   kinase IV/protein serine/threonine phosphatase 2A signaling complex.";
RL   J. Biol. Chem. 279:31708-31716(2004).
RN   [16]
RP   ENZYME REGULATION, AND PROTEIN PHOSPHATASE 2A BINDING DOMAIN.
RX   PubMed=15769749; DOI=10.1074/jbc.M500067200;
RA   Chow F.A., Anderson K.A., Noeldner P.K., Means A.R.;
RT   "The autonomous activity of calcium/calmodulin-dependent protein
RT   kinase IV is required for its role in transcription.";
RL   J. Biol. Chem. 280:20530-20538(2005).
RN   [17]
RP   FUNCTION IN DENDRITIC CELLS LIFESPAN REGULATION, AND DEVELOPMENTAL
RP   STAGE.
RX   PubMed=17909078; DOI=10.1182/blood-2007-05-091173;
RA   Illario M., Giardino-Torchia M.L., Sankar U., Ribar T.J., Galgani M.,
RA   Vitiello L., Masci A.M., Bertani F.R., Ciaglia E., Astone D.,
RA   Maulucci G., Cavallo A., Vitale M., Cimini V., Pastore L., Means A.R.,
RA   Rossi G., Racioppi L.;
RT   "Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling
RT   with survival pathway of activated dendritic cells.";
RL   Blood 111:723-731(2008).
RN   [18]
RP   FUNCTION.
RX   PubMed=18829949; DOI=10.1523/JNEUROSCI.2625-08.2008;
RA   Fukushima H., Maeda R., Suzuki R., Suzuki A., Nomoto M., Toyoda H.,
RA   Wu L.J., Xu H., Zhao M.G., Ueda K., Kitamoto A., Mamiya N.,
RA   Yoshida T., Homma S., Masushige S., Zhuo M., Kida S.;
RT   "Upregulation of calcium/calmodulin-dependent protein kinase IV
RT   improves memory formation and rescues memory loss with aging.";
RL   J. Neurosci. 28:9910-9919(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   GLYCOSYLATION AT THR-57 SER-58; SER-137; SER-189; SER-344; SER-345 AND
RP   SER-356, PHOSPHORYLATION AT THR-200, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF 57-THR-SER-58 AND SER-189.
RX   PubMed=19506079; DOI=10.1074/jbc.M109.007310;
RA   Dias W.B., Cheung W.D., Wang Z., Hart G.W.;
RT   "Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc
RT   modification.";
RL   J. Biol. Chem. 284:21327-21337(2009).
RN   [21]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=9920409; DOI=10.1016/S0167-4889(98)00142-6;
RA   Krebs J.;
RT   "Calmodulin-dependent protein kinase IV: regulation of function and
RT   expression.";
RL   Biochim. Biophys. Acta 1448:183-189(1998).
RN   [22]
RP   REVIEW ON FUNCTION IN NEURONAL PLASTICITY.
RX   PubMed=18817731; DOI=10.1016/j.neuron.2008.08.021;
RA   Wayman G.A., Lee Y.S., Tokumitsu H., Silva A.J., Silva A.,
RA   Soderling T.R.;
RT   "Calmodulin-kinases: modulators of neuronal development and
RT   plasticity.";
RL   Neuron 59:914-931(2008).
RN   [23]
RP   REVIEW ON INVOLVEMENT IN IMMUNE AND INFLAMMATORY RESPONSE.
RX   PubMed=18930438; DOI=10.1016/j.it.2008.08.005;
RA   Racioppi L., Means A.R.;
RT   "Calcium/calmodulin-dependent kinase IV in immune and inflammatory
RT   responses: novel routes for an ancient traveller.";
RL   Trends Immunol. 29:600-607(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-360, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 15-340 IN COMPLEX WITH
RP   INHIBITOR.
RA   Muniz J.R.C., Rellos P., Gileadi O., Fedorov O., Filippakopoulos P.,
RA   Salah E., Pike A., Phillips C., Niesen F., Shrestha L.,
RA   Burgess-Brown N., Bullock A., Berridge G., Vondelft F., Edwards A.M.,
RA   Bountra C., Arrowsmith C.H., Weigelt J., Knapp S.;
RT   "Crystal structure of human CAMK4 in complex with 4-amino(sulfamoyl-
RT   phenylamino)-triazole-carbothioic acid (2,6-difluoro-phenyl)-amide).";
RL   Submitted (NOV-2008) to the PDB data bank.
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-150; ASN-178; ARG-465 AND MET-469.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that
CC       operates in the calcium-triggered CaMKK-CaMK4 signaling cascade
CC       and regulates, mainly by phosphorylation, the activity of several
CC       transcription activators, such as CREB1, MEF2D, JUN and RORA,
CC       which play pivotal roles in immune response, inflammation, and
CC       memory consolidation. In the thymus, regulates the CD4(+)/CD8(+)
CC       double positive thymocytes selection threshold during T-cell
CC       ontogeny. In CD4 memory T-cells, is required to link T-cell
CC       antigen receptor (TCR) signaling to the production of IL2, IFNG
CC       and IL4 (through the regulation of CREB and MEF2). Regulates the
CC       differentiation and survival phases of osteoclasts and dendritic
CC       cells (DCs). Mediates DCs survival by linking TLR4 and the
CC       regulation of temporal expression of BCL2. Phosphorylates the
CC       transcription activator CREB1 on 'Ser-133' in hippocampal neuron
CC       nuclei and contribute to memory consolidation and long term
CC       potentiation (LTP) in the hippocampus. Can activate the MAP
CC       kinases MAPK1/ERK2, MAPK8/JNK1 and MAPK14/p38 and stimulate
CC       transcription through the phosphorylation of ELK1 and ATF2. Can
CC       also phosphorylate in vitro CREBBP, PRM2, MEF2A and STMN1/OP18.
CC       {ECO:0000269|PubMed:10617605, ECO:0000269|PubMed:17909078,
CC       ECO:0000269|PubMed:18829949, ECO:0000269|PubMed:7961813,
CC       ECO:0000269|PubMed:8065343, ECO:0000269|PubMed:8855261,
CC       ECO:0000269|PubMed:8980227, ECO:0000269|PubMed:9154845}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by Ca(2+)/calmodulin. Binding of
CC       calmodulin results in conformational change that relieves
CC       intrasteric autoinhibition and allows phosphorylation of Thr-200
CC       within the activation loop by CaMKK1 or CaMKK2. Phosphorylation of
CC       Thr-200 results in a 10-20-fold increase in total activity to
CC       generate Ca(2+)/calmodulin-independent activity.
CC       Autophosphorylation of the N-terminus Ser-12 and Ser-13 is
CC       required for full activation. Inactivated by protein phosphatase
CC       2A (PPP2CA/PPP2CB) which dephosphorylates Thr-200, thereby
CC       terminating autonomous activity and helping to maintain the enzyme
CC       in its autoinhibited state. {ECO:0000269|PubMed:15143065,
CC       ECO:0000269|PubMed:15769749, ECO:0000269|PubMed:8702940}.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts with protein
CC       phosphatase 2A (PPP2CA/PPP2CB); the interaction is mutually
CC       exclusive with binding to Ca(2+)/calmodulin. {ECO:0000250,
CC       ECO:0000269|PubMed:15143065, ECO:0000269|Ref.27}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Localized in
CC       hippocampal neuron nuclei. In spermatids, associated with
CC       chromatin and nuclear matrix (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain, thymus, CD4 T-cells,
CC       testis and epithelial ovarian cancer tissue.
CC       {ECO:0000269|PubMed:12065094, ECO:0000269|PubMed:7961813,
CC       ECO:0000269|PubMed:8397199}.
CC   -!- DEVELOPMENTAL STAGE: Expressed during differentiation of monocyte-
CC       derived dendritic cells (at protein level).
CC       {ECO:0000269|PubMed:17909078}.
CC   -!- DOMAIN: The autoinhibitory domain overlaps with the calmodulin
CC       binding region and interacts in the inactive folded state with the
CC       catalytic domain as a pseudosubstrate.
CC       {ECO:0000269|PubMed:7961813}.
CC   -!- PTM: Phosphorylated by CaMKK1 and CaMKK2 on Thr-200.
CC       Dephosphorylated by protein phosphatase 2A. Autophosphorylated on
CC       Ser-12 and Ser-13. {ECO:0000269|PubMed:15143065,
CC       ECO:0000269|PubMed:19506079, ECO:0000269|PubMed:8702940}.
CC   -!- PTM: Glycosylation at Ser-189 modulates the phosphorylation of
CC       CaMK4 at Thr-200 and negatively regulates its activity toward
CC       CREB1 in basal conditions and during early inomycin stimulation.
CC       {ECO:0000269|PubMed:15143065, ECO:0000269|PubMed:19506079,
CC       ECO:0000269|PubMed:8702940}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. CaMK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH16695.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D30742; BAA06403.1; -; mRNA.
DR   EMBL; L17000; AAA35639.1; -; mRNA.
DR   EMBL; L24959; AAA18251.1; -; mRNA.
DR   EMBL; CH471086; EAW49033.1; -; Genomic_DNA.
DR   EMBL; CH471086; EAW49034.1; -; Genomic_DNA.
DR   EMBL; BC016695; AAH16695.2; ALT_INIT; mRNA.
DR   EMBL; BC025687; AAH25687.1; -; mRNA.
DR   CCDS; CCDS4103.1; -.
DR   PIR; A53036; A53036.
DR   RefSeq; NP_001310303.1; NM_001323374.1.
DR   RefSeq; NP_001310304.1; NM_001323375.1.
DR   RefSeq; NP_001735.1; NM_001744.5.
DR   UniGene; Hs.438801; -.
DR   UniGene; Hs.591269; -.
DR   PDB; 2W4O; X-ray; 2.17 A; A=15-340.
DR   PDBsum; 2W4O; -.
DR   ProteinModelPortal; Q16566; -.
DR   SMR; Q16566; -.
DR   BioGrid; 107264; 12.
DR   DIP; DIP-41997N; -.
DR   IntAct; Q16566; 1.
DR   MINT; MINT-192934; -.
DR   STRING; 9606.ENSP00000282356; -.
DR   BindingDB; Q16566; -.
DR   ChEMBL; CHEMBL2494; -.
DR   GuidetoPHARMACOLOGY; 1955; -.
DR   iPTMnet; Q16566; -.
DR   PhosphoSitePlus; Q16566; -.
DR   BioMuta; CAMK4; -.
DR   DMDM; 2499586; -.
DR   EPD; Q16566; -.
DR   MaxQB; Q16566; -.
DR   PaxDb; Q16566; -.
DR   PeptideAtlas; Q16566; -.
DR   PRIDE; Q16566; -.
DR   DNASU; 814; -.
DR   Ensembl; ENST00000282356; ENSP00000282356; ENSG00000152495.
DR   Ensembl; ENST00000512453; ENSP00000422634; ENSG00000152495.
DR   GeneID; 814; -.
DR   KEGG; hsa:814; -.
DR   UCSC; uc003kpf.4; human.
DR   CTD; 814; -.
DR   DisGeNET; 814; -.
DR   GeneCards; CAMK4; -.
DR   HGNC; HGNC:1464; CAMK4.
DR   HPA; CAB004347; -.
DR   HPA; HPA011753; -.
DR   HPA; HPA017206; -.
DR   MIM; 114080; gene.
DR   neXtProt; NX_Q16566; -.
DR   OpenTargets; ENSG00000152495; -.
DR   PharmGKB; PA26050; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; ENOG410XRMJ; LUCA.
DR   GeneTree; ENSGT00760000118944; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG108055; -.
DR   InParanoid; Q16566; -.
DR   KO; K05869; -.
DR   OMA; QQDVILP; -.
DR   OrthoDB; EOG091G0HK9; -.
DR   PhylomeDB; Q16566; -.
DR   TreeFam; TF351230; -.
DR   BRENDA; 2.7.11.17; 2681.
DR   Reactome; R-HSA-111932; CaMK IV-mediated phosphorylation of CREB.
DR   Reactome; R-HSA-442717; CREB phosphorylation through the activation of CaMKK.
DR   Reactome; R-HSA-442745; Activation of CaMK IV.
DR   SignaLink; Q16566; -.
DR   SIGNOR; Q16566; -.
DR   ChiTaRS; CAMK4; human.
DR   EvolutionaryTrace; Q16566; -.
DR   GeneWiki; CAMK4; -.
DR   GenomeRNAi; 814; -.
DR   PMAP-CutDB; Q16566; -.
DR   PRO; PR:Q16566; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000152495; -.
DR   CleanEx; HS_CAMK4; -.
DR   ExpressionAtlas; Q16566; baseline and differential.
DR   Genevisible; Q16566; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IDA:CACAO.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007616; P:long-term memory; IGI:UniProtKB.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; TAS:UniProtKB.
DR   GO; GO:0033081; P:regulation of T cell differentiation in thymus; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; ATP-binding; Calcium;
KW   Calmodulin-binding; Complete proteome; Cytoplasm; Glycoprotein;
KW   Immunity; Inflammatory response; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    473       Calcium/calmodulin-dependent protein
FT                                kinase type IV.
FT                                /FTId=PRO_0000086106.
FT   DOMAIN       46    300       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      52     60       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      305    321       Autoinhibitory domain.
FT   REGION      306    323       PP2A-binding.
FT   REGION      322    341       Calmodulin-binding. {ECO:0000255}.
FT   ACT_SITE    164    164       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      75     75       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      12     12       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8702940}.
FT   MOD_RES      13     13       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8702940}.
FT   MOD_RES     200    200       Phosphothreonine; by CaMKK1 and CaMKK2.
FT                                {ECO:0000269|PubMed:15143065,
FT                                ECO:0000269|PubMed:19506079,
FT                                ECO:0000269|PubMed:8702940}.
FT   MOD_RES     336    336       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     341    341       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P13234}.
FT   MOD_RES     360    360       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   CARBOHYD     57     57       O-linked (GlcNAc) threonine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD     58     58       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD    137    137       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD    189    189       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD    344    344       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD    345    345       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   CARBOHYD    356    356       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:19506079}.
FT   VARIANT     150    150       E -> G (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040604.
FT   VARIANT     178    178       D -> N (in dbSNP:rs35548075).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040605.
FT   VARIANT     465    465       Q -> R (in dbSNP:rs56360861).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040606.
FT   VARIANT     469    469       I -> M (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040607.
FT   MUTAGEN      12     12       S->A: Loss of activity.
FT                                {ECO:0000269|PubMed:8702940}.
FT   MUTAGEN      13     13       S->A: Loss of activity.
FT                                {ECO:0000269|PubMed:8702940}.
FT   MUTAGEN      57     58       TS->AA: Loss of phosphorylation of CREB1.
FT                                {ECO:0000269|PubMed:19506079}.
FT   MUTAGEN      75     75       K->E: Loss of activity; dominant negative
FT                                form. {ECO:0000269|PubMed:10617605}.
FT   MUTAGEN     189    189       S->A: Increases phosphorylation of CREB1
FT                                2-fold. Decreases total O-linked
FT                                glycosylation 2-fold. Increases ATP-
FT                                binding affinity.
FT                                {ECO:0000269|PubMed:19506079}.
FT   MUTAGEN     200    200       T->A: Loss of activation by CaMKK1 or
FT                                CaMKK2. {ECO:0000269|PubMed:8855261}.
FT   MUTAGEN     309    312       HMDT->DEDD: Fully active Ca2+/CaM-
FT                                independent kinase; when associated with
FT                                320-A-A-321.
FT                                {ECO:0000269|PubMed:7961813}.
FT   MUTAGEN     320    321       FN->DD: Fully active Ca2+/CaM-independent
FT                                kinase; when associated with 309-A--A-
FT                                312. Loss of interaction with
FT                                PPP2CA/PPP2CB.
FT                                {ECO:0000269|PubMed:15143065,
FT                                ECO:0000269|PubMed:7961813}.
FT   STRAND       36     38       {ECO:0000244|PDB:2W4O}.
FT   HELIX        42     44       {ECO:0000244|PDB:2W4O}.
FT   STRAND       46     54       {ECO:0000244|PDB:2W4O}.
FT   STRAND       56     65       {ECO:0000244|PDB:2W4O}.
FT   TURN         66     68       {ECO:0000244|PDB:2W4O}.
FT   STRAND       71     78       {ECO:0000244|PDB:2W4O}.
FT   HELIX        91     95       {ECO:0000244|PDB:2W4O}.
FT   STRAND      104    109       {ECO:0000244|PDB:2W4O}.
FT   STRAND      111    118       {ECO:0000244|PDB:2W4O}.
FT   HELIX       126    130       {ECO:0000244|PDB:2W4O}.
FT   HELIX       138    157       {ECO:0000244|PDB:2W4O}.
FT   HELIX       167    169       {ECO:0000244|PDB:2W4O}.
FT   STRAND      170    176       {ECO:0000244|PDB:2W4O}.
FT   STRAND      181    183       {ECO:0000244|PDB:2W4O}.
FT   HELIX       205    207       {ECO:0000244|PDB:2W4O}.
FT   HELIX       210    213       {ECO:0000244|PDB:2W4O}.
FT   HELIX       221    236       {ECO:0000244|PDB:2W4O}.
FT   HELIX       247    255       {ECO:0000244|PDB:2W4O}.
FT   TURN        263    268       {ECO:0000244|PDB:2W4O}.
FT   HELIX       271    278       {ECO:0000244|PDB:2W4O}.
FT   HELIX       285    287       {ECO:0000244|PDB:2W4O}.
FT   HELIX       291    296       {ECO:0000244|PDB:2W4O}.
FT   TURN        298    301       {ECO:0000244|PDB:2W4O}.
FT   HELIX       311    335       {ECO:0000244|PDB:2W4O}.
SQ   SEQUENCE   473 AA;  51926 MW;  EFEE51E5612326DC CRC64;
     MLKVTVPSCS ASSCSSVTAS AAPGTASLVP DYWIDGSNRD ALSDFFEVES ELGRGATSIV
     YRCKQKGTQK PYALKVLKKT VDKKIVRTEI GVLLRLSHPN IIKLKEIFET PTEISLVLEL
     VTGGELFDRI VEKGYYSERD AADAVKQILE AVAYLHENGI VHRDLKPENL LYATPAPDAP
     LKIADFGLSK IVEHQVLMKT VCGTPGYCAP EILRGCAYGP EVDMWSVGII TYILLCGFEP
     FYDERGDQFM FRRILNCEYY FISPWWDEVS LNAKDLVRKL IVLDPKKRLT TFQALQHPWV
     TGKAANFVHM DTAQKKLQEF NARRKLKAAV KAVVASSRLG SASSSHGSIQ ESHKASRDPS
     PIQDGNEDMK AIPEGEKIQG DGAQAAVKGA QAELMKVQAL EKVKGADINA EEAPKMVPKA
     VEDGIKVADL ELEEGLAEEK LKTVEEAAAP REGQGSSAVG FEVPQQDVIL PEY
//
